Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Divi's Laboratories Ltd.
NSE: DIVISLAB
|
BSE: 532488
|
ISIN: INE361B01024
|
Industry: Pharmaceuticals
|
Expensive Star
6001.5000
-146.50
(
-2.38
%)
NSE
May 08, 2025
14:49 PM
Near 52W High of ₹6308.50
Volume:
270.4K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Divi's Laboratories Ltd.
05 Nov 2019
6001.50
-2.38%
Divi's Labs (ADD): Good Q2 beat; FY20 margin guidance cut is negative
Buy:
Divi's Laboratories Ltd.
by
BOB Capital Markets Ltd.
Target: 1765
Recommendation
Target
BOB Capital Markets Ltd.
Overall Revenue/EBITDA were 13% ahead of our estimates but largely in-line with consensus.
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended
Market trades lower, Canara Bank's net profit grows 33.1% YoY to Rs 5,002.7 crore in Q4
Trendlyne Marketwatch |
08 May 2025, 02:44PM
Superstar investor portfolios take a hit from market volatility | Screener: Promoters reducing their stakes
The Baseline |
08 May 2025, 12:37AM
Custom synthesis business drives growth for Divi’s Laboratories
|
10 Mar 2022